it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done..

cambridge's bluebird bio licenses delivery tech to novartis, gsk.

.

labour�s new study is based on freedom of information data from 95 english nhs trust..

richard lipton, md, director, montefiore headache center; edwin s. lowe professor and vice chairman of neurology, albert einstein college of medicine..

.
.
.

no wonder he needs such a large army of trained helpers in and around the press.